9 results about "Valsartan" patented technology

The present application relates to a kind of valsartan-2-amino pyridine co-amorphous and preparation method, the co-amorphous of valsartan-2-amino pyridine of the present application is with 2-amino pyridine according to specific proportion mixed, using solvent evaporation method to prepare single-phase amorphous binary system, the present application uses the interaction between 2-amino pyridine and valsartan, forms ternary hydrogen bond connection mode, greatly improves the solubility and dissolution of valsartan, improves bioavailability, and cost is low, energy consumption is low, can large-scale industrial production.

The application belongs to the technical field of medicine synthesis, and particularly relates to a synthesis and refining method of valsartan. After L-valseril is used to prepare a crude valsartan product, ultrasonic-assisted crystallization is used to obtain high-purity valsartan. The synthesis and refining method significantly reduces the content of D-isomer, avoids multiple purification treatment steps, is simple in process and easy to operate, and provides a method for recovering L-valseril from a valsartan mother liquor, so as to further improve the utilization rate, reduce the cost, and be suitable for industrial production.

The utility model provides a parallel micro-channel reaction system which comprises a feeding pump A, a feeding pump B, an ultrasonic flowmeter A, an ultrasonic flowmeter B, a check valve, a feeding pipe A, a feeding pipe B, a micro-channel reactor A, a micro-channel reactor B, a high-low temperature integrated circulator, a discharging pipe A, a discharging pipe B, a combined pipeline and a reaction tank, the high-low temperature integrated circulator is connected with the micro-channel reactor A and the micro-channel reactor B through a circulating freezing liquid pipe A and a circulating freezing liquid pipe B, and the reaction tank is used for containing a reaction solution. The parallel micro-channel reaction system not only improves the yield of the sacubitril valsartan sodium intermediate, but also fills the technical blank that the micro-channel reactors are not used in commercial mass production in the market and no double-plate parallel micro-channel reactor exists, is suitable for capacity expansion of all micro-channel reactors, and has no amplification effect.

This invention belongs to the field of pharmaceutical technology, and specifically relates to a vildagliptin-valsartan co-amorphous compound, its preparation method, and its application. The co-amorphous compound comprises vildagliptin and valsartan; the molar ratio of vildagliptin to valsartan in the co-amorphous compound is 1:0.5-3. In this invention, vildagliptin and valsartan interact to form hydrogen bonds. This interaction not only prevents solvent-mediated drug recrystallization but also accelerates the dissolution and exudation of valsartan. Compared to the valsartan raw material, the solubility and dissolution rate of valsartan in this co-amorphous compound are significantly improved, while the solubility and dissolution rate of vildagliptin are reduced. This is beneficial for improving the bioavailability of valsartan, delaying the release and absorption of vildagliptin in vivo, and the co-amorphous compound exhibits good stability.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The invention belongs to the technical field of biological medicines, and particularly relates to application of an angiotensin II receptor antagonist in preparation of a medicine for preventing and treating renal tubular injury caused by triptolide. According to the invention, the upstream key target protein of the TPL-induced renal tubule injury is determined to be HSPA1 through experiments for the first time, and the problem that the key target spot of TPL toxicity is not determined in the prior art is solved. Based on a key target spot of TPL toxicity, through molecular screening and parallel pharmacodynamic verification on various sartan drugs such as irbesartan, losartan, olmesartan and valsartan, it is determined that the angiotensin II receptor antagonist has a general protection effect on TPL toxicity. Wherein the protective efficacy of irbesartan as a preferable embodiment is obviously superior to that of losartan of the same kind (the efficiency slope is 2.451 to 1.584).

The invention discloses a supramolecular group composite peptide-containing antihypertensive composition, which is composed of raw materials and basic energy substrates, the raw materials comprise composite peptide, phytosterol, taurine and the like, and the basic energy substrates comprise proteins, dietary fibers, fatty acids and / or lipids; the composite peptide is composed of Anbenefit milk polypeptide and balsam pear peptide. According to the present invention, the components of the specific types and the specific amounts are selected and compounded, such that the prepared composition has effects of significant cardiac output reducing and blood vessel diameter increasing, and the partial composition can cooperate with valsartan (antihypertensive drug) to achieve effects of synergistic blood pressure reducing so as to provide effects of auxiliary improvement or prevention of blood pressure reducing. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a valsartan tablet with improved dissolution rate and moisture absorption resistance and a preparation process thereof. The valsartan tablet formula comprises a main drug valsartan and auxiliary materials such as a filler, a disintegrating agent, a stable dissolution promoter, a cosolvent, an adhesive, a surfactant, a lubricant and the like, and the stable dissolution promoter is formed by compounding specific components and needs to be subjected to special treatment of low-temperature crushing and composite grinding. The preparation process adopts wet granulation and comprises the steps of pretreatment of auxiliary materials, premixing, granulation, drying, size stabilization, total mixing, tabletting and the like. According to the invention, the synergistic effect of improving the dissolution rate and optimizing the moisture absorption resistance is realized through a specifically combined stable dissolution promoter and a matched process.

The invention discloses a tablet containing valsartan and an SGLT-2 inhibitor and a preparation method of the tablet, and the tablet is prepared from the following components in parts by weight: 90-165 parts of valsartan, 7-24 parts of the SGLT-2 inhibitor, 115-1250 parts of microcrystalline cellulose and mannitol co-treatment substance, 1.5-5 parts of a lubricant and 11-20 parts of a disintegrating agent. According to the tablet containing the valsartan and the SGLT-2 inhibitor provided by the invention, the valsartan and the SGLT-2 inhibitor are prepared into the compound tablet, so that the medication frequency of a patient can be reduced, a treatment scheme is simplified, and the compliance of the patient can be improved, especially for elderly patients or groups with dysphagia.